press enter »
placeholder
placeholder

Biogen scraps two late-stage trials for Alzheimer's treatment

Biogen scraps two late-stage trials for Alzheimer's treatment

(Reuters) - Biogen Inc and Eisai Co Ltd are abandoning two late-stage trials for their Alzheimer’s treatment in a widely anticipated move that comes months after the companies scrapped trials of another drug for the memory-robbing disease. The companies said on Friday the decision was based on the results of a review conducted by a data safety monitoring

Biogen scraps two late-stage Alzheimer's trials

Biogen scraps two late-stage Alzheimer's trials

(Reuters) - Biogen Inc and partner Eisai Co Ltd said on Friday they would abandon two late-stage trials testing their experimental treatment, elenbecestat, for patients with early Alzheimer’s disease. The companies said the decision was based on the results of a safety review conducted by a data safety monitoring board, which recommended to discontinue